AcuityMD, a Boston-based provider of health data tools for the medical technology sector, has secured $80 million in Series C funding, bringing its total capital raised to more than $160 million and valuing the company at $955 million.
The funding round was led by existing investor StepStone Group, with participation from Redpoint Ventures, Benchmark, ICONIQ, and Atreides Management. The company plans to use the proceeds to further develop its agentic AI capabilities, strengthen its underlying data model, and accelerate growth of its commercial intelligence platform for MedTech organizations.
AcuityMD’s platform, currently in open beta, integrates datasets spanning medical device sales and patient outcomes. It is designed to help MedTech companies evaluate product performance, understand reimbursement dynamics, identify target physicians and healthcare facilities, and assess market share positioning.
"AI will transform MedTech, but only with the right context, deeply embedded in the workflows where decisions are made. AcuityMD is that context layer, serving the rep in the field, the commercial leader planning territories and the teams launching the next generation of innovation. I'm grateful to the hundreds of customers who have helped shape our platform," said Mike Monovoukas, CEO and cofounder of AcuityMD.
He added, "This funding accelerates our shared mission of accelerating adoption of cutting-edge medical technologies."
The Series C round follows a progression of earlier financings, including $45 million raised in a Series B round in 2024 and $31 million in Series A funding two years prior. The company also secured $7 million in seed funding in 2021.
AcuityMD operates within a competitive landscape that includes companies such as Definitive Healthcare, which provides commercial intelligence, data, and analytics solutions focused on healthcare providers, claims data, and market trends.
Click here for the original news story.
